rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Although afatinib inhibited the growth of lung cancer cells with low T790M allele frequencies in preclinical studies, this could not be translated into clinical efficacy in terms of lowering the rate or delaying the time of T790M acquisition.
|
31030101 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Of the 12 cases of NTRK1+ lung cancer, 6 had had concurrent activating EGFR mutations and/or had received previous treatment with EGFR tyrosine kinase inhibitors (TKIs), with 2 having concurrent EGFR T790M and 1 additional EGFR C797S.
|
31761448 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study.
|
31407509 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-small-cell lung cancer (NSCLC) represents 85% of lung cancer in elderly patients.In the present study performed in the 36 elderly subjects with epidermal growth factor receptor (EGFR) T790M mutation-positive NSCLC, osimertinib 80 mg demonstrated statistically significant improvement in the objective response rate, which was comparable to those in the nonelderly population.Osimertinib appears to be an effective and safe treatment option in elderly patients with advanced NSCLC with EGFR mutation; further research in larger scale is warranted.
|
30651400 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
A 79-year-old woman had disease progression during third-line treatment with osimertinib for an EGFR L858R/T790M-mutant lung cancer.
|
31254668 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Notably, the patient with EGFR-T790M germline mutation had multiple maternal family members diagnosed with lung cancers, strongly supporting its role in inherited lung cancer.
|
30610926 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells.
|
31426517 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells.
|
30866688 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Correction: Monitoring <i>EGFR</i>-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
|
31069018 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Peripheral blood sampling for detection of EGFR T790M in cell-free circulating tumour (ct) DNA in TKI-resistant EGFR mutant (EGFRm) lung cancer is now standard.
|
31027703 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer.
|
31393074 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we demonstrate that apigenin combined with gefitinib inhibits multiple oncogenic drivers such as c-Myc, HIF-1α, and EGFR, reduces Gluts and MCT1 protein expression, and inactivates the 5' adenosine monophosphate-activated protein kinase (AMPK) signaling, which regulates glucose uptake and maintains energy metabolism, leading to impaired energy utilization in EGFR L858R-T790M-mutated H1975 lung cancer cells.
|
30967777 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.
|
30885357 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Its clinical utility has been well demonstrated for EGFR T790M testing in lung cancer patients suffering progress after tyrosine kinase inhibitor treatment.
|
31620244 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Lessons learned from routine, targeted assessment of liquid biopsies for <i>EGFR</i> T790M resistance mutation in patients with <i>EGFR</i> mutant lung cancers.
|
31347936 |
2019 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
|
29907952 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
|
29482151 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
|
30073261 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.
|
30151614 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Our findings suggest that radiotherapy combined HS-10182 is a novel treatment for lung cancer cells which have acquired the T790M mutation.
|
29545967 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Cumulative survival from the time of rebiopsy to the last follow-up was significantly longer in patients with T790M mutation-positive lung cancers (P = .014).
|
30015588 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
We developed experimental brain metastasis models by intraventricular injection (intraventricular injection mouse model; IVM) of HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung cancer (NCI-H1975-luc) cells.
|
29321587 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Several ultra-sensitive methods for T790M in plasma cell-free DNA (cfDNA) have been developed for lung cancer.
|
30444875 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
After sequential treatment with first- and third-generation EGFR tyrosine kinase inhibitors (TKIs), EGFR-mutant non-small cell lung cancers frequently harbor multiple resistance mutations in exon 20 of EGFR including T790M, mediating resistance to first-generation TKIs, and at codons 792, 796, or 797 mediating resistance to third-generation TKIs.
|
30481207 |
2018 |
rs121434569
|
EGFR;EGFR-AS1
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation |
BEFREE |
Therefore, germline <i>EGFR</i> T790M mutations result in a unique inherited lung cancer syndrome targeting never smokers.
|
30225213 |
2018 |